{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:42:40Z","timestamp":1779910960495,"version":"3.53.1"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T00:00:00Z","timestamp":1394409600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090963","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T20:44:08Z","timestamp":1394484248000},"page":"e90963","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review"],"prefix":"10.1371","volume":"9","author":[{"given":"Martin C. S.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry H. X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy W. M.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy D. X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirin Q. L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sky W. M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen K. M.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C. Y.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon T. S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,3,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Feinglos MN, Bethel MA (2008) Type 2 diabetes mellitus : an evidence-based approach to practical management. Totowa, NJ: Humana Press.","DOI":"10.1007\/978-1-60327-043-4"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc06-0062","article-title":"Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002","volume":"29(6)","author":"CC Cowie","year":"2006","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-8227(98)00125-9","article-title":"Prevalence of diabetes in Catalonia (Spain): an oral glucose toleratence test-based population study","volume":"43(1)","author":"C Castell","year":"1999","journal-title":"Diabetes Res Clin Pract"},{"key":"ref4","first-page":"781","article-title":"The prevalence of type II diabetes mellitus in rural urban population over 35 years of age in Lublin region (Eastern Poland)","volume":"Wewnetrznej106(3)","author":"J Lopatynski","year":"2001","journal-title":"Polskie Archiwum Medycyny"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00038-012-0364-y","article-title":"The rising tide of diabetes mellitus in a Chinese population: a population-based household survey on 121,895 persons","volume":"58(2)","author":"MC Wong","year":"2013","journal-title":"Int J Public Health"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","article-title":"Prevalence of diabetes among men and women in China","volume":"362(12)","author":"W Yang","year":"2010","journal-title":"NEJM"},{"key":"ref7","unstructured":"International Diabetes Federation Diabetes Atlas Fifth Edition (2012) Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.idf.org\/diabetesatlas\/5e\/the-global-burden\" xlink:type=\"simple\">http:\/\/www.idf.org\/diabetesatlas\/5e\/the-global-burden<\/ext-link>. Accessed 27 August 2013."},{"key":"ref8","unstructured":"Diabetes Statistics American Diabetes Association (2011) Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.diabetes.org\/diabetes-basics\/diabetes-statistics\" xlink:type=\"simple\">http:\/\/www.diabetes.org\/diabetes-basics\/diabetes-statistics<\/ext-link>.Accessed 27 August 2013."},{"key":"ref9","unstructured":"World Health Organization. Diabetes Atlas : Western Pacific Region (2012) Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.idf.org\/diabetesatlas\/?menu_id=2008417121010\" xlink:type=\"simple\">http:\/\/www.idf.org\/diabetesatlas\/?menu_id=2008417121010<\/ext-link>. Accessed 27 August 2013."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321(7258)","author":"AI Adler","year":"2000","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2337\/diacare.28.12.2901","article-title":"Type 2 diabetes as a \u201ccoronary heart disease equivalent\u201d: an 18-year prospective population-based study in Finnish subjects","volume":"28(12)","author":"A Juutilainen","year":"2005","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6963-13-7","article-title":"Type II diabetes patients in primary care: profiles of healthcare utilization obtained from observational data","volume":"13","author":"CE Van Dijk","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2337\/diacare.27.2.553","article-title":"Management of Diabetes and Hyperglycemia in Hospitals","volume":"27(2)","author":"S Clement","year":"2004","journal-title":"Diabetes Care"},{"key":"ref14","unstructured":"Sicree R, Shaw J, Zimmet P (2009) The Global Burden - Diabetes and Impaired Glucose Tolerance. Baker IDI Heart and Diabetes Institute. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.idf.org\/sites\/default\/files\/The_Global_Burden.pdf\" xlink:type=\"simple\">http:\/\/www.idf.org\/sites\/default\/files\/The_Global_Burden.pdf<\/ext-link>. Accessed 27 August 2013."},{"key":"ref15","first-page":"95","article-title":"Management of non-insulin-dependent diabetes mellitus","volume":"343(8889)","author":"W Gareth","year":"1994","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus","volume":"333","author":"RA DeFronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"ref17","first-page":"574","article-title":"Metformin. N Engl J Med","volume":"334(9)","author":"CJ Bailey","year":"1996"},{"key":"ref18","first-page":"854","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352(9131)","year":"1998","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","article-title":"Metabolic effects of metformin in non-insulin-dependent diabetes mellitus","volume":"333(9)","author":"M Stumvoll","year":"1995","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial","volume":"103(6)","author":"AJ Garber","year":"1997","journal-title":"Am J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2337\/diacare.10.6.671","article-title":"Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment","volume":"10(6)","author":"L Groop","year":"1987","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2337\/diacare.19.11.1194","article-title":"Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group","volume":"19(11)","author":"J Rosenstock","year":"1996","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.20.4.597","article-title":"Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group","volume":"20(4)","author":"DC Simonson","year":"1997","journal-title":"Diabetes Care"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/j.1552-4604.1998.tb04471.x","article-title":"A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful","volume":"l38(7)","author":"DS Schade","year":"1998","journal-title":"J Clin Pharmaco"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1185\/030079907X178766","article-title":"Oral antidiabetic agents in type 2 diabetes","volume":"23(4)","author":"C Levetan","year":"2007","journal-title":"Curr med Res Opin"},{"key":"ref26","first-page":"2427","article-title":"Glycemic durability or rosiglitazone, metformin, or glyburide monotherapy","volume":"355(23)","author":"SE Kahn","year":"2007","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1592\/phco.27.8.1102","article-title":"Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy","volume":"27(8)","author":"AA Riedel","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref28","first-page":"837","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352(9131)","year":"1998","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Eldor R, Raz I (2012) Diabetes therapy-focus on Asia: second-line therapy debate: insulin\/secretagogues. Diabetes Metab Res Rev (Suppl 2): 85\u201389.","DOI":"10.1002\/dmrr.2358"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group","volume":"23(11)","author":"S Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355(23)","author":"SE Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption","volume":"11(8)","author":"Y Guan","year":"2005","journal-title":"Nat Med"},{"key":"ref33","first-page":"1191","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170(14)","author":"SE Nissen","year":"2010","journal-title":"Arch Intern Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(01)05842-1","article-title":"Insulins today and beyond","volume":"358(9283)","author":"DR Owens","year":"2001","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/414799a","article-title":"Insulin signalling and the regulation of glucose and lipid metabolism","volume":"414(6865)","author":"AR Saltiel","year":"2001","journal-title":"Nature"},{"issue":"1)","key":"ref36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1463-1326.2008.00881.x","article-title":"Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study","volume":"10(Suppl","author":"FA Guisasola","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"ref37","first-page":"2461","article-title":"Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone","volume":"124(16)","author":"SL Zhang","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"ref38","first-page":"677","article-title":"Inadequate glycaemic control and antidiabetic therapy among inpatients with type 2 diabetes in Guangdong Province of China","volume":"121(8)","author":"BI Yan","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"ref39","unstructured":"Task Force on Conceptual Model and Preventive Protocols, Working Group on Primary Care, Food and Health Bureau (2010) Module 6, Drug Treatment for Hyperglycaemia, Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care Setting. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.pco.gov.hk\/english\/resource\/files\/professionals_DM_Module6.pdf\" xlink:type=\"simple\">http:\/\/www.pco.gov.hk\/english\/resource\/files\/professionals_DM_Module6.pdf<\/ext-link>. Accessed 27 August 2013."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, <etal>et al<\/etal>.. (2013) Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev (10).","DOI":"10.1186\/1472-6823-10-20"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Barnett AH, Grice J (2011) Chapter 4, New Mechanisms in Glucose Control, Oxford: Wiley-Blackwell.","DOI":"10.1002\/9781118682197"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00125-005-1707-5","article-title":"Dipeptidyl peptidase inhibitors as a new drugs for the treatment of type 2 diabetes","volume":"48(4)","author":"J Mest H","year":"2005","journal-title":"Diabetolgia"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diabres.2008.10.009","article-title":"Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea","volume":"83(1)","author":"V Mohan","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3132\/dvdr.2006.024","article-title":"Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes","volume":"3","author":"BD Green","year":"2006","journal-title":"Diabetes Vasc Dis Res"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Barnett AH, Grice J (2011) Chapter 5, New Mechanisms in Glucose Control. Oxford: Wiley-Blackwell.","DOI":"10.1002\/9781118682197"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ (2010) Textbook of diabetes, 4th edition, Oxford, UK: Wiley-Blackwell.","DOI":"10.1002\/9781444324808"},{"key":"ref47","unstructured":"FDA Drug Safety Podcast: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/DrugSafetyPodcasts\/ucm344232.htm\/\" xlink:type=\"simple\">http:\/\/www.fda.gov\/Drugs\/DrugSafety\/DrugSafetyPodcasts\/ucm344232.htm\/<\/ext-link>. Accessed 27 August 2013."},{"key":"ref48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1463-1326.2009.01194.x","article-title":"Improved glycaemic control withminimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes","volume":"12(4)","author":"K Kaku","year":"2010","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.2040-1124.2012.00193.x","article-title":"The once-daily human glucagon-like peptide-1 analog, liraglutide, improves beta-cell function in Japanese patients with type 2 diabetes","volume":"3(4)","author":"Y Seino","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.2040-1124.2010.00084.x","article-title":"Improved glycemic control and reducedbodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks","volume":"2(3)","author":"T Kadowaki","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.clinthera.2012.07.007","article-title":"Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study","volume":"34(9)","author":"N Inagaki","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"ref52","first-page":"910","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14(10)","year":"2012","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/dom.12110","article-title":"Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1year in Japanese patients with type 2 diabetes","volume":"15(9)","author":"N Inagaki","year":"2013","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1185\/03007995.2013.805123","article-title":"Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: A sub-analysis of data from a randomised clinical trial","volume":"29(8)","author":"Z Zeng","year":"2013","journal-title":"Current Medical Research and Opinion"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/dom.12055","article-title":"Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: The COMPASS randomized controlled trial","volume":"15(5)","author":"M Takihata","year":"2013","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.2040-1124.2012.00226.x","article-title":"Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study","volume":"3(6)","author":"Y Seino","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Dipeptidyl peptidase (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2).","DOI":"10.1002\/14651858.CD006739.pub2"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2009.726","article-title":"Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology","volume":"301(20)","author":"CN Chan","year":"2009","journal-title":"JAMA"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibiros between Asians and non-Asians: a systematic review and meta-analysis","volume":"56(4)","author":"YG Kim","year":"2013","journal-title":"Diabetologia"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/dmrr.2413","article-title":"Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)- TIMI 53 trial","volume":"29(5)","author":"O Mosenzon","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369(14)","author":"BM Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369(14)","author":"WB White","year":"2013","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/dmrr.296","article-title":"Diabetes trends in Japan","volume":"18","author":"R Kawamori","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabres.2006.01.013","article-title":"The status of diabetes control and antidiabetic drug therapy in Japan \u2013 a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)","volume":"73(2)","author":"M Kobayashi","year":"2006","journal-title":"Diabetes Res Clin Pract"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:14:07Z","timestamp":1565255647000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090963"}},"subtitle":[],"editor":[{"given":"Fran\u00e7ois","family":"Blachier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,10]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090963","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,10]]}}}